BioSpace News Archive

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study with Cleveland Clinic. The study will assess the effects of DSUVIA on post-o

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Appli

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® 9%.

Ortho Regenerative Technologies Inc., an emerging orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced the closing of a non-brokered $2.5 million private placement of units.

Focus on Yumanity’s lead clinical program in Parkinson’s disease and transformative pipeline of disease-modifying treatments for neurogenerative disorders

$98.7M financing, development fees and commercial milestone commitments accelerate the development and commercialization of One Drop’s digital health platform and data-driven predictive capabilities across multiple therapeutic areas

Humanigen, Inc. announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a sales agreement with a Texas-based laboratory to supply it with the necessary testing equipment and supplies for

Home care services encompass a wide variety of services offered to individuals who cannot take care of themselves.

According to the report, the global ornithine transcarbamylase (OTC) deficiency treatment market was valued at ~US$ 600 Mn in 2019.